Last reviewed · How we verify
NCT06898944
Prognosis and Risk Factors for Acute Kidney Injury
trial in Acute Kidney Injury in 320,000 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 320,000 |
| Start date | 22 August 2022 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across South Korea |
Conditions studied
- Acute Kidney Injury — all drugs for Acute Kidney Injury →
Sponsor
Seoul National University Hospital
Who can join
20 and older, any sex, with Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of our study is to analyze the accurate diagnosis and prognosis of acute kidney injury (AKI) based on its severity and to define long-term clinical and socioeconomic outcomes. Investigators defined the AKI group among adults aged 20 years or older who visited enrolled center and underwent at least two blood tests, including serum creatinine, within an interval of 7 days or less and a control group was matched 1:1 to the AKI group based on age, sex, year of visit, and baseline kidney function, forming the study population. Investigators then collected and analyzed various clinical, laboratory, and hospitalization records including demographic data, anthropometric data, laboratory data, and medical history.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06898944
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Kidney Injury
Currently open trials in the same condition.
- NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
- NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
- NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
- NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
- NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06898944 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 2 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06898944.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing